Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
UCBUCBJY -0.50%92 FCF Margin % is -1.80% as of Jun. 2026. GuruFocus rates UCBJY with a GF Score™ of 92/100 and a GF Value™ of $142.61 (Modestly Undervalued). Among 952 Biotechnology companies, UCB ranks better than 86.66% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. UCB's Free Cash Flow for the
six
months ended in Jun. 2026 was $-89 Mil. UCB's Revenue for the
six
months ended in Jun. 2026 was $4,919 Mil. Therefore, UCB's FCF Margin % for the quarter that ended in Jun. 2026 was -1.80%.
The historical data trend for UCB's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UCBJY vs VRTX, REGN, RVMD: FCF Margin % Comparison
For the Biotechnology subindustry, UCB's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
UCB FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, UCB's FCF Margin % distribution charts can be found below:
* The bar in red indicates where UCB's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UCB (UCBJY) has a FCF Margin % of -1.80% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on UCB and its competitors. Over the past decade, UCB's FCF Margin % has ranged from 6.97 to 23.80. According to the industry distribution chart, UCB ranks #127 out of 952 companies in the Biotechnology industry, placing it in the top 13.3%.
Is UCB's FCF Margin % too high?
UCB's current FCF Margin % is -1.80%. Over the past 10 years, this metric has ranged from a low of 6.97 to a high of 23.80. Based on the distribution chart, UCB ranks #127 out of 952 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, UCB has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does UCB's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, UCB ranks #127 out of 952 companies for FCF Margin %. This places UCB in the top 13% of its industry — outperforming the majority of peers. Historically, UCB's own FCF Margin % has ranged from 6.97 to 23.80 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on UCB and its competitors. UCB's current FCF Margin % is -1.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UCB stock overvalued right now?
Based on GuruFocus' analysis, UCB (UCBJY) is currently considered Modestly Undervalued. The stock's GF Value™ is $142.61, compared to a current price of $127.88 — trading 10.3% below its estimated fair value. The current FCF Margin % is -1.80%. UCB's overall GF Score™ is 92/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For UCB (UCBJY), the current FCF Margin % is -1.80% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is UCB (UCBJY) Overvalued in 2026?
Based on GuruFocus' analysis, UCB stock appears to be undervalued.
The current stock price of $127.88 is trading 10.3% below its estimated GF Value™ of $142.61.
GuruFocus considers UCB to be Modestly Undervalued.
Key valuation signals for UCBJY:
FCF Margin %: -1.80%
GF Value™: $142.61 vs. price of $127.88 (10.3% below fair value)
No single metric tells the full story. See the UCBJY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome), and Kygevvi (rare mitochondrial disease).
92GF Score
Get the complete analysis for UCBJY
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
UCBJY has been successfully added to your 
